Novo Nordisk A/S (NVO) Stock Price, News & Analysis

Novo Nordisk A/S logo
$40.55 -1.05 (-2.51%)
As of 03:34 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Novo Nordisk A/S Stock (NYSE:NVO)

Advanced

Key Stats

Today's Range
$40.23
▼
$40.96
50-Day Range
$37.31
▼
$45.15
52-Week Range
$35.12
▼
$64.16
Volume
13.03 million shs
Average Volume
16.31 million shs
Market Capitalization
$181.07 billion
P/E Ratio
10.22
Dividend Yield
2.02%
Price Target
$59.44
Consensus Rating
Hold

Company Overview

Novo Nordisk A/S is a Danish pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes insulin and other diabetes medicines, as well as obesity treatments such as Wegovy and diabetes treatments such as Ozempic and Rybelsus.

The company also develops medicines for rare blood and endocrine disorders, including hemophilia and growth disorders. Its products are sold in markets around the world.

Novo Nordisk traces its roots to Danish insulin companies founded in the 1920s; the two organizations that became Novo Nordisk merged in 1989. The company is headquartered in Bagsværd, Denmark.

AI Generated. May Contain Errors.

Novo Nordisk A/S Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
79th Percentile Overall Score

NVO MarketRank™: 
3.94565937707 of 5 stars

Novo Nordisk A/S scored higher than 79% of companies evaluated by MarketBeat, and ranked 96th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Novo Nordisk A/S has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 5 buy ratings, 16 hold ratings, and 5 sell ratings.

  • Upside Potential

    Novo Nordisk A/S has a consensus price target of $59.44, representing about 46.2% upside from its current price of $40.67.

  • Amount of Analyst Coverage

    Novo Nordisk A/S has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Novo Nordisk A/S's stock forecast and price target.
  • Earnings Growth

    Earnings for Novo Nordisk A/S are expected to grow by 2.07% in the coming year, from $3.38 to $3.45 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Novo Nordisk A/S is 10.24, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.02.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Novo Nordisk A/S is 10.24, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.24.

  • Price to Earnings Growth Ratio

    Novo Nordisk A/S has a PEG Ratio of 1.40. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Novo Nordisk A/S has a P/B Ratio of 5.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Novo Nordisk A/S's valuation and earnings.
  • Percentage of Shares Shorted

    0.86% of the float of Novo Nordisk A/S has been sold short.
  • Short Interest Ratio / Days to Cover

    Novo Nordisk A/S has a short interest ratio ("days to cover") of 4.04.
  • Change versus previous month

    Short interest in Novo Nordisk A/S has recently increased by 2.27%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Novo Nordisk A/S pays a meaningful dividend of 2.01%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Novo Nordisk A/S does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Novo Nordisk A/S is 20.65%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Novo Nordisk A/S will have a dividend payout ratio of 23.77% next year. This indicates that Novo Nordisk A/S will be able to sustain or increase its dividend.

  • Read more about Novo Nordisk A/S's dividend.
  • News Sentiment

    Novo Nordisk A/S has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 32 news articles for Novo Nordisk A/S this week, compared to 7 articles on an average week.
  • Search Interest

    Only 54 people have searched for NVO on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.
  • MarketBeat Follows

    31 people have added Novo Nordisk A/S to their MarketBeat watchlist in the last 30 days. This is an increase of 138% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Novo Nordisk A/S insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    0.07% of the stock of Novo Nordisk A/S is held by insiders.

  • Percentage Held by Institutions

    11.54% of the stock of Novo Nordisk A/S is held by institutions.

  • Read more about Novo Nordisk A/S's insider trading history.
Receive NVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novo Nordisk A/S and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NVO Stock News Headlines

Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
Johnson & Johnson vs. Novo Nordisk: Steady Uptrend vs. Flat Revenue
Johnson & Johnson vs. Novo Nordisk: Steady Uptrend vs.
Hims & Hers logo overlaid on medical syringes, measuring tape, and financial charts symbolizing telehealth weight-loss market growth.
Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-Off (NVO)
Hims & Hers stock sank after a Q3 earnings and revenue miss, lower EBITDA guidance, subscriber declines, and an expanding FTC lawsuit over privacy and billing practices.
4 Beaten-Down Stocks With Catalysts Ahead, Including 1 Down More Than 50%
Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts (NVO)
MercadoLibre, Novo Nordisk, Tyler Technologies and Summit Therapeutics trade below recent highs, yet each has earnings or catalysts that could shift sentiment.
See More Headlines

NVO Stock Analysis - Frequently Asked Questions

Novo Nordisk A/S's stock was trading at $50.88 on January 1st, 2026. Since then, NVO shares have decreased by 20.1% and is now trading at $40.6650.

Novo Nordisk A/S (NYSE:NVO) announced its quarterly earnings data on Wednesday, August, 5th. The company reported $0.96 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.19. The company earned $11.98 billion during the quarter, compared to analyst estimates of $10.89 billion. Novo Nordisk A/S had a net margin of 33.99% and a trailing twelve-month return on equity of 53.52%.
Read the conference call transcript
.

Novo Nordisk A/S's stock split on Wednesday, September 20th 2023.The 2-1 split was announced on Wednesday, September 20th 2023. The newly minted shares were payable to shareholders after the closing bell on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

The following companies are subsidiaries of Novo Nordisk A/S: Dicerna Pharmaceuticals, Emisphere Technologies, Corvidia Therapeutics, Ziylo, Calibrium, MB2 LLC, Xellia Pharmaceuticals, and others.

Top institutional shareholders of Novo Nordisk A/S include Dodge & Cox (0.46%), Fisher Asset Management LLC (0.18%), Everett Harris & Co. CA (0.14%) and State Street Corp (0.13%).
View institutional ownership trends
.

Shares of NVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Novo Nordisk A/S investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Eli Lilly and Company (LLY), Tesla (TSLA), Broadcom (AVGO), Palantir Technologies (PLTR) and Taiwan Semiconductor Manufacturing (TSM).

Company Calendar

Last Earnings
8/05/2026
Record date for 8/25 Dividend
8/17/2026
Ex-Dividend for 8/25 Dividend
8/17/2026
Dividend Payable
8/25/2026
Today
11/17/2026
Fiscal Year End
12/31/2026
Next Earnings (Estimated)
2/03/2027

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NYSE:NVO
CIK
353278
Employees
69,505
Year Founded
1923

Price Target and Rating

High Price Target
$175.00
Low Price Target
$38.00
Potential Upside/Downside
+46.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
26 Analysts

Profitability

EPS (Trailing Twelve Months)
$3.97
Trailing P/E Ratio
10.22
Forward P/E Ratio
11.76
P/E Growth
1.4
Net Income
$15.51 billion
Net Margins
33.99%
Pretax Margin
43.58%
Return on Equity
53.52%
Return on Assets
19.49%

Debt

Debt-to-Equity Ratio
0.54
Current Ratio
0.84
Quick Ratio
0.64

Sales & Book Value

Annual Sales
$46.80 billion
Price / Sales
3.87
Cash Flow
$4.68 per share
Price / Cash Flow
8.67
Book Value
$7.51 per share
Price / Book
5.40

Miscellaneous

Outstanding Shares
4,465,000,000
Free Float
4,461,875,000
Market Cap
$181.08 billion
Optionable
Optionable
Beta
0.70

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NYSE:NVO) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners